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Debate on Statistical Significance
Many researchers have questioned the acceptability of 
p-values in medical decision-making, and considerable 
research exists into how p-values are misused.2,3 For exam-
ple, in his seminal paper, Cohen4 argued that: “NHST is highly 
flawed as it is relatively easy to achieve results that can be 
labeled significant when a ‘nil’ hypothesis is used rather 
than a true ‘null’ hypothesis.” In recent years, despite its 
success, there is an emerging debate about whether to use 
p-values to describe statistically significant scientific results 
due to its frequent failure to reproduce and replicate simi-
lar statistically significant findings. Halsey et al5 argued that: 
“the p-value is often used without the realization that in 
most cases the statistical power of a study is too low for p 
to assist the interpretation of the data.… Researchers would 
do better to discard the p-value and use alternative statisti-
cal measures for data interpretation.” In agreement with this 
thinking, the journal of Basic and Applied Social Psychology 
recently barred p-values and hypothesis testing from articles 
published in their journal.6 p-Values are also susceptible to 
“hacking,” to demonstrate statistical significance when no 
association exists and encourages selective reporting of only 
positive findings. A recent methodological review of articles 
published in high impact journals suggests that significant 
results are about twice as likely to be reported as nonsignif-
icant results.7
In our opinion, p-values alone cannot be responsible 
for the lack of reproducibility of research findings, as it is 
often a combination of methodological errors and interpre-
tation. Like other statistical measures, the p-value is also a 
one-dimensional metric and based on data; thus, it could 
be misleading when calculated from relatively small sam-
ples. The overall selection of statistical methods, including 
the lack of randomness in the sample and missing data, can 
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Introduction
Statistical significance is the bedrock of evidence-based 
medicine, crucial for decision-making and framing biomedi-
cal science policies. The emergence of complex data in many 
disciplines, resulting from the analysis of large datasets, has 
amplified the popularity of p-values. Its simplicity allows 
investigators to conclude and disseminate their research 
findings in a manner understood by most. Thus, obtaining 
a p-value that indicates “statistical significance” against the 
null hypothesis is often required for publishing in medical 
journals. However, it creates challenges due to nonreproduc-
ibility, misuse and overinterpretation, which lead to serious 
methodological errors. This article aims to draw biomedical 
researchers' attention toward the appropriate use of p-values 
in clinical decision-making.
Historical Development
Fisher first introduced null hypothesis significance testing 
(NHST) in 1925.1 Subsequently, p-values became the stan-
dard of reporting and judging scientific evidence's strength 
when testing the null hypotheses against the alternative 
proposition in most scientific disciplines, including biomedi-
cal research. The recent development of big data research has 
made p-values even more popular to test the significance of 
study findings and has become a sine qua non for publishing 
in medical journals. The basis of the p-value is that it com-
putes the probability of observing results at least as extreme 
as the ones observed, given that the null hypothesis is correct 
and compared against a predetermined significance level (α). 
If the reported p-value is lesser than α, the test result is to 
be considered statistically significant (►Fig. 1). Typically, α is 
set arbitrarily at 0.05 level to control false-positive rate, and 
other commonly used significance levels are 0.01 and 0.001.
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also influence the statistical significance that may result in 
misleading p-values. Misinterpretation of the p-value as a 
measure of the strength of association, rather than its true 
meaning (assessing the probability for a given result arising 
due to chance), is a glaring indictment of the current bio-
medical teaching standards. A recent methodological survey 
of statistical methods in Indian journals suggests that no sig-
nificant progress has been achieved regarding the correct use 
of statistical analyses.8
Suggested Alternatives on Statistical 
Significance
Several alternatives to p-values have been suggested in the 
literature, such as confidence intervals and Bayesian statis-
tics.9 A confidence interval provides the point estimate with 
uncertainty bounds that can be more informative than a 
p-value. However, confidence intervals are like p-values when 
testing the null hypothesis's acceptance or rejection and chal-
lenging to compare between studies due to unit-dependence. 
In Bayesian statistics, the credible interval, equivalent to the 
frequentist approach's confidence interval, is another possi-
ble alternative to the p-value. Both alternative methods are 
like the p-value when testing the null hypothesis for clinical 
decision-making and can misinterpret the results' clinical 
or biological importance. Recently, Benjamin et al proposed 
to lower the p-value (the conventional “statistical signifi-
cance”) threshold from 0.05 to 0.005 for all novel claims with 
relatively low prior odds, to avoid high false positives and 
improve the reproducibility of scientific research.10 However, 
others have argued that research should be guided by rig-
orous scientific principles, not by heuristics and arbitrary 
thresholds. These principles include sound statistical analy-
ses, replication, validation and generalization, avoidance of 
logical traps, intellectual honesty, research workflow trans-
parency, and accounting for potential sources of error.11,12
Guidance on Appropriate Interpretation of 
Statistical Significance
Therefore, educating researchers with appropriate training 
on concepts and relevant software could be one alternative 
to prevent misinterpretation of the p-value. It is worth reit-
erating Fisher’s initial view that p-values should be one part 
of the evidence used when deciding whether to reject the 
null hypothesis. Appropriate guidance should also be taken 
during the design, process and data analysis of a study from 
various available resources such as Consolidated Standards 
of Reporting Trials (CONSORT)13 for clinical trials, Preferred 
Reporting Items for Systematic reviews and Meta-Analyses 
(PRISMA)14 for systematic reviews and meta-analysis, 
Strengthening the Reporting of Observational Studies in 
Epidemiology (STROBE)15 for observational studies, and 
Transparent Reporting of a multivariable prediction model 
for Individual Prognosis Or Diagnosis (TRIPOD)16 for risk pre-
diction from a multivariable model.
As mentioned in NHST approach, researchers commonly 
classify results as statistically “significant” or “not-significant,” 
based on whether the p-value is smaller than some prespec-
ified cut point value (usually 0.05). However, this practice is 
becoming obsolete, and exact p-values are preferred by lead-
ing medical journals such as the British Medical Journal (BMJ), 
Journal of the American Medical Association (JAMA), and the 
Lancet. Guidance should be taken from Fisher’s1 belief about 
p-values from his 1925 book and Efron’s17 interpretation on 
observed p-values (or achieved significance level) as pre-
sented in ►Table  1. The American Statistical Association 
(ASA) took this matter to their board in 2015 and discussed 
it with renowned statisticians in multiple rounds for several Fig. 1 Definition of p-value (https://en.wikipedia.org/wiki/Statistics).
Table 1  Fisher’s belief and Efron’s interpretation of observed p-values
Fisher’s beliefs regarding p-values Efron’s interpretations of achieved significance levels
p-value Fisher’s statements Achieved significance 
levels (ASL)
Interpretation
0.1–0.9 Certainly, no reason to suspect the hypothesis 
tested
ASL < 0.10 Borderline evidence against the null 
hypothesis
0.02–0.05 Judged significant, though barely so … these 
data do not, however, demonstrate the point 
beyond the possibility of doubt
ASL < 0.05 Reasonably strong evidence against the 
null hypothesis
< 0.02 Strongly indicated that the hypothesis fails to 
account for the whole of the facts
ASL < 0.025 Strong evidence against the null 
hypothesis
< 0.01 No practical importance of whether p-value is 
0.01 or 0.000001
ASL < 0.01 Very strong evidence against the null 
hypothesis
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months. Further, a “statement on statistical significance and 
p-values” with six principles has been released by ASA at the 
beginning of 2016 to guide researchers and avoid any misuse 
and misinterpretation.18 In its statement, the ASA advised 
researchers to avoid drawing scientific conclusions or mak-
ing policy decisions purely based on p-values. Additionally, 
they recommend describing the data analysis approach that 
produces statistically significant results, including all statisti-
cal tests and choices made in calculations. Otherwise, results 
may appear misleadingly robust.
Conclusion
In conclusion, we advocate that statistics should be used as 
a science rather than a recipe for the desired flavor. While 
researchers want certainty, they must understand that sta-
tistics is a science of uncertainty. Thus, solely relying on a 
single p-value to describe the scientific value of a study is a 
misuse of the p-value and when evaluating the strength of 
any evidence, researchers need to explain their results in the 
light of theoretical considerations such as scope, explanatory 
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